Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase ( n 2) and accelerated phase ( n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, r...

Full description

Bibliographic Details
Main Authors: Mariana Serpa, Sabri S. Sanabani, Israel Bendit, Fernanda Seguro, Flávia Xavier, Cláudia Bitti Barroso, Monika Conchon, Pedro Enrique Dorlhiac-Llacer
Format: Article
Language:English
Published: SAGE Publishing 2010-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S6413

Similar Items

Similar Items